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Abstract: Although schizophrenia has been diagnosed in children, this group of disorders has 
received too little attention in the clinical and research literature. Preliminary data suggest that 
early onset schizophrenia (EOS) and very early onset schizophrenia (VEOS) tend to have a worse 
outcome than adult onset schizophrenia, and seem to be related to a greater familial vulnerability, 
due to genetic, psychosocial, and environmental factors. Recently, advanced neuroimaging 
techniques have revealed structural and functional brain abnormalities in some cerebral areas. 
This paper reports on a case diagnosed as VEOS, with premorbid year-long psychopathological 
history. The patient showed atypical proton magnetic resonance spectroscopy ﬁ  ndings, and 
normal brain and spine computer tomography and brain magnetic resonance images.
Keywords: very early onset schizophrenia, early onset schizophrenia, premorbid neurodevel-
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Introduction
Schizophrenia comprises a group of chronic and debilitating psychiatric disorders, 
characterized by abnormalities in thinking, perception, and emotion. Schizophrenia 
is rare in children, affecting about 1 in 1,000, compared to 1 in 100 in adults, with a 
male/female rate of 1.67 (Campbell et al 1997; Nicolson and Rapoport 1999).
Several studies suggest a clinical continuity between early and later onset schizo-
phrenia (Jacobsen and Rapoport 1998; Nicolson and Rapoport 1999; Asarnow et al 
2004). The Diagnostic and Statistical Manual for Mental Disorders, IV Edition (APA 
2000) and the International Classiﬁ  cation of Disease, X Edition (WHO 1992) propose 
the same general diagnostic criteria for both forms of schizophrenia. Recently, two 
classiﬁ  cations have been identiﬁ  ed based on the age of onset: early onset schizophrenia 
(EOS), when the psychotic symptoms are present after the age of 13 years, and very 
early onset schizophrenia (VEOS), when the onset is at or before the age of 13 years 
(Werry 1992; Russel 1994). EOS and VEOS show atypical features when compared 
with adult-onset schizophrenia (AOS): insidious onset; more severe premorbid 
neurodevelopmental abnormalities; more frequent terrifying visual hallucinations; 
constant inappropriate or blunted affects; higher rate of familial psychopathology; 
minor response to treatment; and poorer outcome. Preliminary data suggest that 
VEOS and EOS may be secondary to greater familial vulnerability, due to genetic, 
psychosocial, and environmental factors (Werry 1992; Russel 1994; Bailly and de 
Choudy de Lenclave 2004).
The clinical heterogeneity of VEOS-EOS could be due to the peculiarity of 
developmental psychopathology, rather than to physiopathological differences between 
children and adults.
Recent research in neuroscience has improved our understanding of the biological 
basis of schizophrenia. Advanced neuroimaging techniques applied to psychiatric Neuropsychiatric Disease and Treatment 2008:4(4) 826
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disorders, such as noninvasive proton and phosphorus 
spectroscopy nuclear magnetic resonance imaging, have 
deﬁ  ned signiﬁ  cant abnormalities in membrane metabolism 
(Stanley et al 1994; Stanley et al 1995; Bertolino et al 1998; 
Auer et al 2001; O’Neill et al 2004; Tanaka et al 2006).
We report a case diagnosed as VEOS, with premorbid 
year-long psychopathological history, who showed atypical 
multivoxel proton magnetic resonance spectroscopy (1H-MRS) 
ﬁ  ndings, with normal brain and spine computer tomography 
(CT) and brain magnetic resonance (MR) images.
Case report
The patient is a 15.3-year-old girl
The psychodiagnostic assessment included semistructured 
interviews and rating scales administered to the patients 
and to their parents (Schedule for Affective Disorders 
and Schizophrenia for School-Age Children - Present and 
Lifetime Version, Child Behavior Checklist, Children 
Depression Rating Scale, Children Depression Inventory, 
Screen for Child Anxiety Related Disorders). The clinical 
and instrumental assessment comprised physical and neuro-
logical examinations, general laboratory investigation, and 
neuroimaging study.
Family history
The family belongs to the upper social class. The father shows 
obsessive personality traits, and was treated with paroxetine; 
the mother is affected by schizotypal personality disorder. 
The 10-year-old brother shows enuresis. The maternal grand-
father is described as introvert and depressed; the maternal 
grandmother as intrusive and hypercritical. A paternal ﬁ  rst 
cousin is affected by anorexia nervosa.
Clinical history
The patient was born by natural delivery at the eighth month 
of gestation, after a physiological pregnancy. At birth she 
evidenced cyanosis and mild respiratory distress. She showed 
mild motor developmental delay. From birth she showed 
poor eye contact, absence of smiling and weeping, severe 
difﬁ  culties in social skills, agitation bursts, and separation 
anxiety. She spent much of her time swinging herself. During 
primary school academic performance was inadequate, as 
was her relationship with peers. At age 9 she showed sleep 
disturbances, enuresis, and visual and auditory hallucina-
tions. Her social withdrawal worsened over time, and was 
associated with bizarre and disorganized behavior. Academic 
performance also declined still further. She was started on 
psychotherapy. She came to our ﬁ  rst observation at the age 
of 11 years. The patient appeared a chubby, clumsy, slow 
girl, dressed as an adult, with a hypomimic, and perplexed 
face. Eye contact was poor. Her speech was digressive, 
overlabored, and affected, with loosening of associations 
and altered prosody. She evidenced poor attention, while 
she showed good writing narrative abilities (she wrote long, 
fantastical histories). She reported visual and auditory hal-
lucinations, and persecutory themes. She was diagnosed as 
suffering from paranoid schizophrenia (according to criteria 
from DSM-IV), and pharmacotherapy with olanzapine was 
started; psychotherapy continued. At age 13, she began to 
exhibit mood swings, aggression, and occasional explosive 
outbursts. Olanzapine was replaced with haloperidol, because 
of weight gain. She showed partial remission over the next 
6 months: the visual hallucinations, and aggression disap-
peared; her behavior became more organized. At the age of 
14.7 years she presented a psychiatry emergency: she felt her-
self to be constantly followed by someone; during the night 
she would often wake up hearing a man weeping, who asked 
her to help him; she heard an imperative, frightening male 
voice in her head, which told her to leave her room; during 
the day she saw scenes of blood. She reported a deep sense 
of confusion, anguish, thoughts of death and suicide, and a 
fear of hurting others. Lorazepam was added to haloperidol. 
She quickly showed a remission of the state of anguish, a 
signiﬁ  cant reduction of the visual hallucinations, and a slight 
improvement of mood. At the last observation, at the age of 
15.3 years, she showed affective ﬂ  attening, sporadic auditory 
hallucinations, sexual disinhibition, bizarre behavior, and 
refusal to attend school.
Neuroimaging study
Brain and spine CT showed normal ﬁ  ndings. Brain MR 
examination showed normal dimensions and morphology 
of cerebral ventricles and no altered signal of parenchyma. 
1H-MRS was performed in the frontal regions and in the 
right semioval center, using the MR General Electric, 
Signa Lx and Mr/I Milwaukee 1.5 Tesla Unit. The 1H-MRS 
protocol consisted of multivoxel water suppressed spectra 
(TR/TE = 2100/96.4) with a voxel size of 20 × 20 × 15 mm. 
1H-MRS showed an elevated peak of lipids in both frontal 
regions (Figure 1a, b), with normal values for N-acetylaspartate 
(NAA), creatine plus phosphocreatine (Cr), and choline (Cho), 
and NAA/Cr and Cho/Cr ratios. The ﬁ  ndings in the right 
semioval center were all normal (Figure 2). The values were 
compared with the values obtained from a control group of 
20 healthy patients aged 10 to 15 years who had undergone 
MRI for headache or epilepsy. In MRI of the control group Neuropsychiatric Disease and Treatment 2008:4(4) 827
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the conventional sequences did not show alterations of 
parenchyma and ventricles. The 1H-MRS (multivoxel water 
suppressed spectra TR/TE = 2100/26.4 with voxel size of 
20 × 20 × 15 mm) showed only NAA, Cho, and Cr peaks at 
normal concentrations, and no peak of lipids.
Discussion
Although schizophrenia has been diagnosed in children, 
this disorder has received too little attention in the clinical 
and research literature. A greater frequency or severity 
of genetic and nongenetic risk factors could result in the 
early onset of schizophrenia; VEOS and EOS provide 
an opportunity to look for the relationships between 
genetic and environmental factors, neurodevelopmental 
abnormalities, and premorbid indicators of schizophrenia 
(Werry 1992; WHO 1992; Asarnow and Asarnow 
1994; Russel 1994; Campbell et al 1997; Jacobsen and 
Rapoport 1998; Nicolson and Rapoport 1999; APA 2000; 
Figure 1a Multivoxel 1H-MRS (by GE Signa LX 1,5 T): axial T2-weighted images (TE 96.4 ms), multivoxel localization at the level of left frontal lobe. 1H-MRS spectra show an 
abnormal peak of lipids.
Figure 1b Multivoxel 1H-MRS (by GE Signa LX 1,5 T): axial T2-weighted images (TE 96.4 ms), multivoxel localization at the level of right frontal lobe.  1H-MRS spectra show 
a peak of lipids.Neuropsychiatric Disease and Treatment 2008:4(4) 828
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Nicolson et al 2000; Asarnow et al 2004; Bailly and de 
Chouly de Lenclave 2004).
Schizophrenia is actually considered to be a neurode-
velopmental disorder: abnormalities in brain development 
and maturation seem to begin prenatally, but continue 
through childhood, and the changes observed over the time 
have consequences for neuronal circuitry and connectivity 
(Watkins et al 1988; Gourion et al 2004; Maki et al 2005). 
Recent research has focused on the premorbid indicators 
of schizophrenia, in order to improve the diagnostic and 
therapeutic interventions in the prodromal phases of the 
illness (Asarnow and Asarnow 1994; Russel 1994; Allen 
et al 2005; Maki et al 2005). In fact, early detection and 
precocious treatment of the ﬁ  rst episode of schizophrenia 
could modify the outcome.
Premorbid abnormalities in academic, motor, lan-
guage, and affective development are considered to be a 
neurodevelopmental marker unique to schizophrenia, social 
deterioration being a more general premorbid feature of 
severe affective and other psychotic illness (Alaghband-
Rad et al 1995; Allen et al 2005). In addition, several 
studies suggest that more pronounced early developmental 
premorbid abnormalities are usually associated with a poor 
outcome (Alaghband-Rad et al 1995). Although these early 
signs and prodromal symptoms can be deﬁ  ned retrospectively 
in patients who have developed schizophrenia, they still 
have to be conﬁ  rmed as early predictors in prospective and 
longitudinal studies.
Recent studies underline the correlation of genetic, 
epigenetic, and environmental factors in the etiopathogenesis 
of schizophrenia, which might explain the heterogeneity of 
symptoms, course, and outcome (Petronis 2004). Molecular 
genetic studies have identified several chromosomal 
abnormalities, and evidence is accumulating in favor of 
several positional candidate genes (Petronis 2004). Familial 
studies have shown that parents of patients with VEOS/EOS 
have higher rates of schizophrenia and related spectrum 
disorders (schizoaffective disorder, schizotypal personality 
disorder, paranoid personality disorder) than parents of 
patients with adulthood-onset illness, and relatives of children 
and adolescents with attention deﬁ  cit hyperactivity disorder 
(Asarnow et al 2001; Nicolson et al 2003). The parents of 
these patients also showed a higher rate of social isolation, 
introversion, suspiciousness, and hostility than parents of 
children with autism and attention deﬁ  cit hyperactivity 
disorder (Asarnow et al 2001; Nicolson et al 2003).
In our patient, premorbid symptoms were present 
from birth, and signs of cognitive, emotional, and behav-
ioral dysfunction were evident over the years. Despite 
these precocious signs, she was not observed medically 
until 9 years of age. Moreover, her parents showed 
several psychopathologies, also of the related spectrum 
disorders, suggesting a greater genetic vulnerability 
associated with acquired environmental factors. Our 
patient is particularly interesting because she provides 
a critical window into the inter-relationships between 
Figure 2 Multivoxel 1H-MRS (by GE Signa LX 1,5 T): axial T2-weighted images (TE 96.4 ms), multivoxel localization at the level of right semioval center. 1H-MRS spectra 
show normal values.Neuropsychiatric Disease and Treatment 2008:4(4) 829
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genetic predisposition, neurodevelopment, and premorbid 
indicators of schizophrenia.
The last two decades of neuroscience research have 
greatly expanded our understanding of the processes 
involved in the human brain’s structural development 
and functional anatomy. There is evidence for structural 
and functional brain abnormalities in schizophrenia, 
suggesting abnormal local cell-energy metabolism and 
phospholipid membrane abnormalities (Stanley et al 
1994, 1995; Bertolino et al 1998; Auer et al 2001; O’Neill 
et al 2004; Tanaka et al 2006). The principal ﬁ  ndings of 
1H-MRS in childhood-onset schizophrenia reveal above-
normal levels of Cr in the superior anterior cingulate; 
above-normal levels of Cho compounds in the superior 
anterior cingulate, frontal cortex, and caudate head; lower 
NAA in the thalamus; and decreased NAA/Cr ratio in the 
frontal cortex and hippocampus (Bertolino et al 1998; 
Auer et al 2001; O’Neill et al 2004; Tanaka et al 2006). 
The most consistent evidence for membrane phospholipid 
abnormalities in schizophrenia derives from phosphorus 
31 magnetic resonance spectroscopy studies, indicating 
reduced membrane phospholipid precursors in early phases 
of schizophrenia (Stanley et al 1995; Auer et al 2001). 
The decreased synthesis and increased breakdown of 
membrane phospholipids might modify the structure and 
function of the neuronal membrane, microenvironment, 
receptors, ion channels, and enzymes, resulting in an altered 
neurotransmission (Fenton et al 2000). Peaks of lipids are 
reported in adolescents with a bipolar disorder (Castillo 
et al 2000), and have never been reported in 1H-MRS study 
in cases with VEOS/EOS. Follow-up studies are needed to 
examine the predictive value of these measures.
Our patient showed unique 1H-MRS ﬁ  ndings. We could 
hypothesize that the 1H-MRS ﬁ  ndings might be a preco-
cious alteration leading to other abnormalities over time, 
consistent with a neurodevelopmental model of this illness, 
but we cannot exclude the possibility that these ﬁ  ndings are 
the result of a progression of the illness, consistent with a 
neurodegenerative model.
Additional clinical studies on childhood schizophrenia 
are required to determine the very early signs and symptoms 
that indicate a VEOS/EOS, and whether the premorbid 
period should not already be regarded as illness, and treated 
accordingly. Further delineation of biological markers is 
necessary to identity the etiopathogenesis of EOS/VEOS. In 
particular, 1H-MRS is a noninvasive investigative technique 
that could provide useful insights into the biochemical basis 
of schizophrenia.
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